To report 2-year efficacy and safety outcomes of 2 dosing regimens of abicipar (every 8 weeks and quarterly, after initial doses) compared with monthly ranibizumab in patients with treatment-naïve neovascular age-related macular degeneration (nAMD).
Two-Year Results of the Phase 3 Randomized Controlled Study of Abicipar in Neovascular Age-Related Macular Degeneration
Bandello, Francesco;
2021-01-01
Abstract
To report 2-year efficacy and safety outcomes of 2 dosing regimens of abicipar (every 8 weeks and quarterly, after initial doses) compared with monthly ranibizumab in patients with treatment-naïve neovascular age-related macular degeneration (nAMD).File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
